Loading viewer...
investor_presentation
Format: PDF investor_presentation
Stefan Oschmann, CEO Marcus Kuhnert, CFO Munich , September 18, 2017MERCK KGAA , DARMSTADT, GERMANY – GOLDMAN SACHS SIXTH GERMAN CORPORATE CONFERENCE
Stefan Oschmann, CEO
Munich , September 18, 2017MERCK KGAA ,
DARMSTADT, GERMANY –
SIXTH GERMAN CORPORATE CONFERENCE2Disclaimer
Publication ofMerck KGaA ,Darmstadt, Germany .IntheUnited States andCanada
thegroup ofcompanies affiliated withMerck KGaA ,Darmstadt, Germany operates
under individual business names (EMD Serono, Millipore Sigma, EMD Performance
Materials) .Toreflect such factandtoavoid anymisconceptions ofthereader ofthe
publication certain logos, terms andbusiness descriptions ofthepublication have
been substituted oradditional descriptions have been added .Thisversion ofthe
publication, therefore, slightly deviates from theotherwise identical version ofthe
publication provided outside theUnited States andCanada .
Cautionary Note Regarding Forward -Looking Statements andfinancial indicators
Thiscommunication may include “forward -looking statements .”Statements thatinclude words such as“anticipate,” “expect,” “should,” “would,” “intend,” “plan,” “project,” “seek,”
“believe,” “will,” andother words ofsimilar meaning inconnection withfuture events orfuture operating orfinancial performance areoften used toidentify forward -looking statements .
Allstatements inthiscommunication, other than those relating tohistorical information orcurrent conditions, areforward -looking statements .Weintend these forward -looking
statements tobecovered bythesafeharbor provisions forforward -looking statements inthePrivate Securities Litigation Reform Actof1995.These forward -looking statements are
subject toanumber ofrisks anduncertainties, many ofwhich arebeyond control ofMerck KGaA ,Darmstadt, Germany, which could cause actual results todiffer materially from such
Risks anduncertainties include, butarenotlimited to:therisks ofmore restrictive regulatory requirements regarding drug pricing, reimbursement andapproval ;theriskofstricter
regulations forthemanufacture, testing andmarketing ofproducts ;theriskofdestabilization ofpolitical systems andtheestablishment oftrade barriers ;theriskofachanging
marketing environment formultiple sclerosis products intheEuropean Union ;theriskofgreater competitive pressure duetobiosimilars ;therisks ofresearch anddevelopment ;the
risks ofdiscontinuing development projects andregulatory approval ofdeveloped medicines ;theriskofatemporary banonproducts/production facilities orofnon-registration of
products duetonon-compliance withquality standards ;theriskofanimport banonproducts totheUnited States duetoanFDAwarning letter ;therisks ofdependency onsuppliers ;
risks duetoproduct -related crime andespionage ;risks inrelation totheuseoffinancial instruments ;liquidity risks;counterparty risks;market risks;risks ofimpairment onbalance
sheet items ;risks from pension obligations ;risks from product -related andpatent lawdisputes ;risks from antitrust lawproceedings ;risks from drug pricing bythedivested Generics
Preview truncated — download the full document for the complete content.